Zydus Cadila gets USFDA approval for cholesterol, psychosis drugs

Zydus Cadila said it received the final approval from the USFDA to market cholesterol-lowering Gemfibrozil and antipsychotic Aripiprazole in the US.

Gemfibrozil Tablets are used together with diet to treat very high cholesterol and triglyceride levels in people with pancreatitis.

It is also used to lower the risk of stroke, heart attack or other heart complications in certain people with high cholesterol and triglycerides who have not benefitted from other treatment methods.

Aripiprazole is an atypical antipsychotic. The drug is used to treat certain mental and mood disorders, such as bipolar disorder, schizophrenia, Tourette’s disorder, and irritability associated with autistic disorder.

It may also be used in combination with other medication to treat depression.

Both drugs will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

With this, Zydus now has 215 approvals and has so far filed over 330 ANDAs since FY 2003-04.